Insider Favorites Nanjing Vazyme Biotech And 2 Other Growth Leaders

As global markets continue to reach new heights, with major indices like the Dow Jones Industrial Average and S&P 500 hitting record intraday highs, investors are closely monitoring economic indicators and geopolitical developments. Amidst this backdrop of robust market activity and policy shifts, growth companies with high insider ownership often attract attention due to their potential for aligning management interests with shareholder value. In this environment, stocks that demonstrate strong growth potential while maintaining significant insider investment can be particularly appealing to investors seeking stability alongside opportunity.

Top 10 Growth Companies With High Insider Ownership

Name	Insider Ownership	Earnings Growth
SKS Technologies Group (ASX:SKS)	32.4%	24.8%
Propel Holdings (TSX:PRL)	36.9%	37.6%
On Holding (NYSE:ONON)	19.1%	29.4%
Pharma Mar (BME:PHM)	11.8%	56.2%
CD Projekt (WSE:CDR)	29.7%	28.6%
Elliptic Laboratories (OB:ELABS)	26.8%	111.4%
EHang Holdings (NasdaqGM:EH)	32.8%	81.5%
Credo Technology Group Holding (NasdaqGS:CRDO)	13.6%	65.9%
Alkami Technology (NasdaqGS:ALKT)	10.8%	98.6%
Brightstar Resources (ASX:BTR)	16.2%	84.6%

Click here to see the full list of 1507 stocks from our Fast Growing Companies With High Insider Ownership screener.

We're going to check out a few of the best picks from our screener tool.

Nanjing Vazyme Biotech (SHSE:688105)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Nanjing Vazyme Biotech Co., Ltd provides technology solutions in life science, biomedicine, and in vitro diagnostics, with a market cap of approximately CN¥9.75 billion.

Operations: Nanjing Vazyme Biotech Co., Ltd generates revenue through its technology solutions in the fields of life science, biomedicine, and in vitro diagnostics.

Insider Ownership: 12.9%

Earnings Growth Forecast: 90% p.a.

Nanjing Vazyme Biotech is experiencing robust growth, with revenue projected to increase by 23.7% annually, outpacing the Chinese market's average. The company's earnings are expected to grow significantly at 90% per year, having turned profitable this year with a net income of CNY 18.16 million compared to a loss previously. Despite high share price volatility and low future return on equity forecasts, insider ownership remains stable without substantial recent trading activity.

• Unlock comprehensive insights into our analysis of Nanjing Vazyme Biotech stock in this growth report.
• Our comprehensive valuation report raises the possibility that Nanjing Vazyme Biotech is priced higher than what may be justified by its financials.

Changchun BCHT Biotechnology (SHSE:688276)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Changchun BCHT Biotechnology Co. Ltd. is a biopharmaceutical company involved in the research, development, production, and sale of human vaccines in China and internationally, with a market cap of CN¥11.09 billion.

Operations: The company generates its revenue from the biotechnology segment, amounting to CN¥1.61 billion.

Insider Ownership: 31.9%

Earnings Growth Forecast: 39.3% p.a.

Changchun BCHT Biotechnology is positioned for substantial growth, with revenue expected to rise 26.9% annually, surpassing the Chinese market's average. Earnings are forecast to grow significantly at 39.31% per year, despite recent declines in net income and sales compared to last year. The company's price-to-earnings ratio of 27.5x suggests it is undervalued relative to the market average of 36.6x, while insider ownership remains stable without significant recent trading activity.

• Delve into the full analysis future growth report here for a deeper understanding of Changchun BCHT Biotechnology.
• The analysis detailed in our Changchun BCHT Biotechnology valuation report hints at an inflated share price compared to its estimated value.

King Slide Works (TWSE:2059)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: King Slide Works Co., Ltd. operates in Taiwan, focusing on the research, development, design, and sale of rail kits for servers and network communication equipment, with a market cap of NT$151.99 billion.

Operations: The company's revenue segments include NT$2.16 billion from Chuanhu Company and NT$7.12 billion from Chuan Yi Company.

Insider Ownership: 14.3%

Earnings Growth Forecast: 14.5% p.a.

King Slide Works has shown impressive financial performance, with earnings growing by 61.3% over the past year and revenue forecasted to grow at 20.4% annually, outpacing the Taiwanese market average. Despite high volatility in share price recently, the company maintains a strong return on equity forecast of 26.7%. Although there is no substantial insider trading activity reported in recent months, King Slide Works' growth trajectory remains robust with significant revenue expansion expected.

• Click to explore a detailed breakdown of our findings in King Slide Works' earnings growth report.
• The valuation report we've compiled suggests that King Slide Works' current price could be inflated.

Summing It All Up

• Gain an insight into the universe of 1507 Fast Growing Companies With High Insider Ownership by clicking here.
• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com